Daily Schedule - Saturday - September 19

Concurrent Sessions 3-4  
8:00 a.m.-10:00 a.m.

Concurrent Session 3: Preclinical Models
Session Chairperson: Philip D. Greenberg, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington

Chairperson perspective
Philip D. Greenberg

Title to be announced
Charles G. Drake, Johns Hopkins Sidney Kimmel Comprehensive Cancer, Baltimore, Maryland

Designing combination immunotherapies to drive synergistic innate and adaptive antitumor immunity
Darrell J. Irvine, MIT Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts

Engineered T cell-receptor based therapy of pancreatic ductal adenocarcinoma
Ingunn M. Stromnes, Fred Hutchinson Cancer Research Institute, Seattle, Washington

TGF-beta1 primed myeloid derived suppressor cells decrease tumor growth and lose their ability to inhibit T cell proliferation via iNOS downregulation*
Padmini Jayaraman, Baylor College of Medicine, Houston, Texas

Concurrent Session 4: Drug Development: Immuno-Oncology Trial Design
Session Chairperson: Axel Hoos, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania

Innovative phase 1 and proof of concept screening studies to accelerate PD-1 antibody development
Roy D. Baynes, Merck Research Laboratories, Rahway, New Jersey

What's next? Interpreting the next wave of cancer immunotherapy studies
Daniel S. Chen, Genentech, Inc., South San Francisco, California

Continuous event monitoring in cancer immunotherapy trials
Tai-Tsang Chen, Bristol-Myers Squibb, Princeton, New Jersey

The evolving use of endpoints in immunotherapy trials
Axel Hoos

Refreshment Break
10:00 a.m.-10:30 a.m.

Plenary Session 7: Clinical Trials of Cancer Immunotherapies, Part 2
Session Chairperson: Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
10:30 a.m.-1:00 p.m.

Mechanisms of protective tumor immunity
Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts

Cancer prevention: Dendritic cell enhanced immune responses towards neoantigens in patients with Lynch syndrome
Jolanda deVries, Centre for Molecular Life Sciences, Nijmegen, The Netherlands

Prospect of a vaccine to prevent cancer in BRCA1-2 mutation carriers
Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

Towards implementation of T-cell therapy in pancreatic cancer
Rienk Offringa, Deutsches Krebsforschungszentrum, Heidelberg, Germany

Non-viral gene transfer to redirect T cell specificity
Laurence J.N. Cooper, The University of Texas MD Anderson Cancer Center, Houston, Texas

1:00 p.m.

*Short talks from proffered abstracts


Top of page